Vol 12, No 3 (June 30, 2023): Chinese Clinical Oncology

Editorial

The future is here—targeted therapies are coming of age in biliary tract cancers

Daniel Neureiter, Matthias Ocker

Chinese Clinical Oncology

2023;

12

(3)

:20

.

(30 June 2023)

PDF Full Text (1262) COI Form Open Access

Original Article

Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis

Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Ana Carolina Marin Comini, Bruno Murad Carvalho, Wilson Nogueira, Hyan Silveira, Brenda J. Ernst, Lida A. Mina

Chinese Clinical Oncology

2023;

12

(3)

:21

.

(30 June 2023)

PDF Full Text (4230) Reporting Checklist Peer Review File COI Form Open Access

Lymph node staging with ⁶⁸Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit

Umberto Vittorio Maestroni, Davide Campobasso, Giulio Guarino, Anna Acampora, Maura Scarlattei, Francesco Ziglioli, Francesco Dinale, Giorgio Baldari, Silvia Migliari, Donatello Gasparro, Stefania Ferretti, Enrico Maria Silini, Livia Ruffini

Chinese Clinical Oncology

2023;

12

(3)

:22

.

(30 June 2023)

PDF Full Text (1758) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial

Louis Cappelli, Mehak Majid Khan, Allison Kayne, Spencer Poiset, Ryan Miller, Ayesha Ali, Muneeb Niazi, Wenyin Shi, Iyad Alnahhas

Chinese Clinical Oncology

2023;

12

(3)

:23

.

(30 June 2023)

PDF Full Text (2073) Data Sharing Statement Peer Review File COI Form Open Access

Review Article

FLOT or CROSS for gastroesophageal junction cancers—is the debate over yet?

Bushra Shariff, Rutika Mehta

Chinese Clinical Oncology

2023;

12

(3)

:24

.

(30 June 2023)

PDF Full Text (5957) Peer Review File COI Form Open Access

CDH1 and hereditary diffuse gastric cancer: a narrative review

Stephanie N. Gregory, Jeremy L. Davis

Chinese Clinical Oncology

2023;

12

(3)

:25

.

(30 June 2023)

PDF Full Text (7868) Reporting Checklist COI Form Open Access

Focal versus whole gland salvage brachytherapy for recurrent prostate cancer in the prostate specific membrane antigen PET era: a narrative review

Lauren M. Andring, Bin S. Teh, Edward Brian Butler, Andrew M. Farach

Chinese Clinical Oncology

2023;

12

(3)

:26

.

(30 June 2023)

PDF Full Text (2500) Reporting Checklist Peer Review File COI Form Open Access

Geographical, ethnic, and genetic differences in pancreatic cancer predisposition

Sherilyn Zi Hui Liew, Kwok Wing Ng, Nur Diana Binte Ishak, Suat Ying Lee, Zewen Zhang, Jianbang Chiang, Joanne Yuen Yie Ngeow

Chinese Clinical Oncology

2023;

12

(3)

:27

.

(30 June 2023)

PDF Full Text (4193) Peer Review File COI Form Open Access

Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review

Yu Jin Jeong, John F. Thompson, Sydney Ch’ng

Chinese Clinical Oncology

2023;

12

(3)

:28

.

(30 June 2023)

PDF Full Text (6189) Reporting Checklist Peer Review File COI Form Open Access

Editorial Commentary

Overview of late complications of radiation therapy in uveal melanoma

Andrew J. Wong, Amy C. Schefler, Bin S. Teh

Chinese Clinical Oncology

2023;

12

(3)

:29

.

(30 June 2023)

PDF Full Text (2248) COI Form Open Access

Is there a role for first generation TKIs in adjuvant setting of EGFR mutated early NSCLC?

Aylen Vanessa Ospina, Mariano Provencio

Chinese Clinical Oncology

2023;

12

(3)

:30

.

(30 June 2023)

PDF Full Text (1090) Peer Review File COI Form Open Access

Re-ORIENT-ing antitumor immunity in EGFR-mutant non-small cell lung cancer: are antiangiogenics the key?

Aaron J. Franke, Erin L. Schenk

Chinese Clinical Oncology

2023;

12

(3)

:31

.

(30 June 2023)

PDF Full Text (1578) COI Form Open Access